Zentalis CEO gets 775,000 stock options grant

Zentalis Pharmaceuticals, Inc. reported an insider equity award for its CEO and President, Julia Marie Eastland, in a Form 4 filing.

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. reported an insider equity award for its CEO and President, Julia Marie Eastland, in a Form 4 filing. On January 8, 2026, she received a grant of stock options to buy 775,000 shares of the company’s common stock at an exercise price of $2.84 per share. These options were reported as held directly, with 775,000 derivative securities beneficially owned following the transaction.

According to the filing, the options will vest over four years in substantially equal monthly installments, and vesting is conditioned on her continued service with the company. There were no sales of stock reported; this filing reflects an award of options rather than a disposition of shares.

Insider Trade Summary

Grant/Award: 775,000 shares

Grant/Award 1 txn

Insider EASTLAND JULIA MARIE

Role CEO & President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	775,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 775,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zentalis Pharmaceuticals (ZNTL) report in this Form 4?

The filing reports that CEO and President Julia Marie Eastland received a grant of stock options covering 775,000 shares of Zentalis Pharmaceuticals, Inc. common stock.

How many Zentalis (ZNTL) stock options were granted to the CEO and at what exercise price?

Julia Marie Eastland was granted 775,000 stock options, each giving the right to buy one share of Zentalis common stock at an exercise price of $2.84 per share.

What are the vesting terms for the 775,000 stock options granted by Zentalis (ZNTL)?

The options will vest over four years in substantially equal monthly installments until fully vested, and vesting is subject to the reporting person’s continued service with Zentalis Pharmaceuticals, Inc.

Did the Zentalis (ZNTL) Form 4 disclose any stock sales by the CEO?

No stock sales were disclosed. The Form 4 reports an award of stock options (transaction code “A”) to the CEO, not a sale or disposal of existing shares.

How many derivative securities does the Zentalis (ZNTL) CEO beneficially own after this transaction?

Following the reported transaction, the Form 4 states that 775,000 derivative securities (stock options) are beneficially owned, held in direct ownership.

What is the expiration date of the Zentalis (ZNTL) stock options granted to the CEO?

The stock options granted on January 8, 2026 have an expiration date of January 7, 2036, as disclosed in the derivative securities table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 08:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EASTLAND JULIA MARIE

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.84	01/08/2026		A		775,000		(1)	01/07/2036	Common Stock	775,000	$0	775,000	D

Explanation of Responses:

1. The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James B. Bucher, attorney-in-fact for Julia Marie Eastland	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.